39 results about "Oxacillin Sodium" patented technology

The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).

The invention discloses a midget anti drug-tolerance staphylococcus aureus polypeptide comprised of passage structure domain to form ion channel colicine and staphylococcus aureu pheromone, as well as opposite coded nucleotide sequence and recombination plasmid contained said sequence. Wherein, the plupeptide can not induce bacteria to generate trsditional drug-tolerance by the mechnism that it forms directly ion channel on cell film of target cell to kill bacteria. This invention has more single antimicrobial spectrum without effect to Gram-negative bacteria of escherichia coli, shows at least 500 times effect to pheneazonecillin, and can be used as synergist to beta-lactam antibiotics.

The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).

The invention relates to a method for detecting oxacillin SERS by using superparamagnetic Fe<3>O<4>@SiO<2>@Ag nano composite material. Fe<3>O<4>@SiO<2>@Ag nano composite material is used as SERS active substrate. The preparation method of the SERS active substrate Fe<3>O<4>@SiO<2>@Ag nano composite material takes Fe<3>O<4> as a core and takes SiO<2> as a shell to construct a Fe<3>O<4>@SiO<2> core-shell structure, Ag nano particles are formed by utilizing the isotropic growth of Ag species and the stabilizing action of polyvinylpyrrolidone (PVP) and are deposited on the core-shell structure, the Fe<3>O<4>@SiO<2>@Ag core-shell structure which is good in dispersion, good in magnetic response, high in sensitivity and integrated is obtained. The method for detecting the oxacillin SERS has the advantages of simplicity, rapidness, high integration, good reproducibility and high sensitivity, and can be used for rapidly detecting the oxacillin in various dosage forms.

The invention discloses a macrolide compound, a synthetic method of the macrolide compound, a pharmaceutical composition and application. The macrolide compound or pharmaceutically acceptable salt thereof shows certain separate anti-MRSA (methicillin-resistant staphylococcus aureus) activity and can further remarkably increase the MRSA inhibiting function of beta-lactam antibiotics when jointly used with the beta-lactam antibiotics. Test results show that the macrolide compound or pharmaceutically acceptable salt has good in-vitro synergism, is a novel synergist, can relieve drug resistance ofthe MRSA to oxacillin and is a drug with good market development prospects.

The invention relates to the organic amine salt or hydrate for Nishibayashi compound used for treating bacteria infection, and the chemical formula is demonstrated in (I). It comprises azlocillin organic amine salt, amoxicillin organic amine salt, ampicillin organic amine salt, oxacillin organic amine salt, furbenicillin organic amine salt, cloxacillin organic amine salt, mezlocillin organic amine salt, mecillin organic amine salt, piperacillin organic amine salt, ticarcillin organic amine salt, flucloxacillin organic amine salt, hetacillin organic amine salt, ortho-chlorocillin organic amine salt, penicillin organic amine salt and their hydrate. The invention provides the medical compound taking compound in formula (I) as active element and its application to preparation of medicine for treating bacteria infection.

The invention relates to the technical field of adsorption materials, in particular to a beta-lactam antibiotic multi-template molecularly imprinted magnetic composite material, a preparation method and application thereof. The invention discloses a beta-lactam antibiotic multi-template molecularly imprinted magnetic composite material, which has strong adsorption selectivity, can specifically andquickly adsorb cefalexin, cefazolin sodium, penicillin G sodium, oxacillin sodium and amoxicillin, and has large adsorption capacity. The composite material also shows superparamagnetism, solid-liquid separation can be rapidly and effectively realized, and the working efficiency is improved. The composite material can be combined with high performance liquid chromatography to be used for detecting the beta-lactam antibiotics in a complex environment water sample, and the beta-lactam antibiotics in the complex environment water sample can be effectively detected and separated.

Contemplated methods and compositions further increase susceptibility of sensitized MRSA against various antibiotic drugs. Most preferably, the MRSA is already sensitized with a galloylated catechin (e.g., ECG), and further sensitization is achieved by exposure to a non-galloylated catechin (e.g., EC), and most preferably the corresponding non-galloylated catechin.

Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria.

The invention provides a method for preparing oxacillin sodium and oxacillin sodium for injection by taking 6-APA and benzyl chloride isoxazole as raw materials, which comprises the steps of condensation, acidification, crystallization, crystal washing, grinding, packaging and the like. The synthesis method of the oxacillin sodium can be stably operated with high efficiency on a large scale, and realizes the synthesis of the oxacillin sodium with high yield, purity and stability on the industrial scale; and furthermore, the method can be used for directly obtaining the oxacillin sodium product for injection by controlling the production environment and process.

The invention belongs to the field of pharmacy, and relates to a benzene polyene sesquiterpene derivative and an application thereof in preparing an anti-resistant-bacteria medicine and preparation, and especially in preparing medicines and preparations used for inhibiting drug-resistant staphylococcus aureus. The benzene polyene sesquiterpene derivative provided by the invention comprises compounds 1 and 2, and is obtained by separation from a traditional Chinese medicine material asafoetida. As a result of test, the derivative has pharmacological activity against drug-resistant staphylococcus aureus. The compound 2 has a minimal inhibitory concentration (MIC) of 2mug / L against tetracycline-resistant staphylococcus aureus strain XU212 and methicillin-resistant staphylococcus aureus strain EMRSA-15, such that the activity is substantially better than control drugs tetracycline and oxacillin. For bacterium drug resistance, the compounds 1 and 2 show significant external pump inhibition effect against resistant staphylococcus aureus RN4220 with MsrA macrolide external pump protein and methicillin-resistant staphylococcus aureus EMRSA-16 with mecA gene. The derivative can be further used for preparing medicine preparations used for resisting external-pump drug-resistant staphylococcus aureus.

The invention relates to a carboxylic acid penicillin dibenzyl (substituting benzyl) ethylenediamine salt compound and an application thereof in preparing a high-purification sodium oxacillin salt. The carboxylic acid penicillin dibenzyl (substituting benzyl) ethylenediamine salt compound has a structure as the formula II, and carboxylic acid penicillin comprises ticacillin, carbenicillin and thelike, wherein R is thiofuran-3-group or phenyl; R1, R2 and R3 are respectively independent H, alkyls of C1-C5, halogens and nitryl; and substituent groups of the substituted alkyl are selected from the halogens and alkoxy groups of C1-C5.

The invention discloses a rhubarb acid ester derivative in the field of antibiotic compounds. The chemical structural formula of rhubarb acid ester is as shown in the formula (II), the formula (II) isshown in the description, wherein R is a chain substituent group of 1-5 carbon atoms or a naphthenic base or an aromatic hydrocarbon group of 3-6 carbon atoms. An antibiotic activity test proves thatthe rhubarb acid ester derivative with the novel structure has the antibiotic activity on methicillin-resistant staphylococcus aureus (MRSA). A plurality of targets have the outstanding antibiotic effect on methicillin-resistant staphylococcus aureus (MRSA), are superior to the reference drug oxacillin and is close to the reference drug vancomycin, and the rhubarb acid ester derivative can be served as a candidate compound to resist methicillin-resistant staphylococcus aureus (MRSA) and be researched.

The invention relates to a Chinese and Western medicine composition for treating burn. The Chinese and Western medicine composition comprises the following traditional Chinese medicines and Western medicines in parts by weight: 90-130 parts of herba houttuyniae, 80-120 parts of folium ginkgo, 50-100 parts of corn stigma, 600-1000 parts of sevelamer hydrochloride, 20-40 parts of rutin, 8-20 parts of concha margaritifera, 5-20 parts of liquorice roots, 3-18 parts of centipedes, 50-100 parts of cortex moutan radicis, 50-80 parts of spiramycin, 4-20 parts of vitamin E, 50-150 parts of enrofloxacin, 200-300 parts of dirithromycin and 60-120 parts of oxacillin sodium. The composition is capable of activating meridians to stop pain, clearing away heat and toxic materials, promoting blood circulation to remove blood stasis, removing slough and promoting tissue regeneration and rapidly repairing epithelium, has a high cure rate, and has special advantage that blood pressure does not need to becontrolled when used for treating burn patients with high blood pressure, so that the curative time is greatly shortened and is basically same as that of an ordinary burn patient.

The invention relates to a bactericidal composition containing bromothalonil and carbazole, the active ingredient of which is a binary compound of bromothalonil and carbazole. Among them, the mass ratio of bromothalonil to carbendazole is 1-25:25-1, the mass ratio of active ingredients bromothalonil to carbendazole in the preparation is 1%-80%, and the rest are allowed to be used and accepted in pesticides. auxiliary components, the dosage form of the bactericidal composition of the present invention is emulsifiable concentrate, suspension concentrate, wettable powder, water, water dispersible granule, water emulsion, microemulsion, granule, microcapsule. Mainly used to control cucumber, grape downy mildew, botrytis and other diseases.

The invention relates to a preparation method of oxacillin film-coated tablets, belonging to the technical field of medicines. The white pill of the oxacillin film-coated tablets is composed of the following components in percentage by weight: 78-90% of oxacillin sodium, 2-4% of talc, 5-10% of starch filler and 0.5-1.5% of magnesium stearate; the film coating agent is composed of the following components in percentage by weight: 3.5-5% of gastric-soluble coating agent, 0.06-0.09% of Tween-80 and 0.09-0.13% of talc; and the coating agent is prepared into a coating solution the solid content ofwhich is 8-11% with a 80% ethanol aqueous solution for use. In the invention, the difficulty in coating oxacillin sodium tablets and irregular tables are solved, and the oxacillin film-coated tabletscan be prepared.

The invention belongs to the field of pharmacy, and relates to an application of spiroketal polyacetylene compounds in preparing sensitizing medicines for resisting efflux pump resistant staphylococcus aureus. Based upon results of bacteriostasis experiments, the spiroketal polyacetylene compounds, in the mode of a synergistic effect, can generate an antibacterial synergistic action on oxacillin;and especially, through combined use of the spiroketal polyacetylene compounds and the oxacillin, the minimum inhibitory concentration of the oxacillin can be obviously reduced, and a resistant staphylococcus aureus synergistic action can be taken on the oxacillin. The spiroketal polyacetylene compounds can be applied to the sensitizing medicines for resisting a multi-drug resistant staphylococcusaureus strain EMRSA-16 containing an mecA efflux pump drug resistance gene, as well as to a pharmaceutical composition which is prepared from the compounds and the oxacillin and has a resistant staphylococcus aureus resisting effect.

The invention discloses a preparation method of oxacillin sodium and oxacillin sodium for injection, and solves the problem that the split charging yield of the oxacillin sodium for injection is low due to poor fluidity of the existing oxacillin sodium powder. The method comprises the following steps of: adding crystallized and dried oxacillin sodium intermediate powder into a ball milling tank, and carrying out ball milling to obtain oxacillin sodium dry powder. The method has the advantages that the flowability of the oxacillin sodium dry powder is good, the yield of the obtained oxacillin sodium for injection is high, and the like.

The invention relates to synthesis and application of an antibacterial medicine ASC for targeted treatment of MRSA (methicillin-resistant staphylococcus aureus) and SAU (staphylococcus aureus) infection and for treatment of super bacterium infection by being cooperated with antibiotics. The effective concentration of the ASC for treating the MRSA infection is 2 mug / mL; the efficacy is 4 times higher than the efficacy of standard medicine oxacillin; the dosage of 35 mg / kg can realize the specific effect treatment on mouse heart and lung MRSA infection, and the MRSA colonization quantity in liver, spleen and kidney tissues of the mouse can be obviously reduced. The ASC is also a broad spectrum inhibitor of antibiotic drug resistant target protein metal beta-lactamase, and can be cooperated with beta-lactamase, aminoglycoside and tetracycline type medicine to realize the targeted treatment of SAU infection; through the dose of 1 mug / mL, the curative effects of antibiotics can be improvedto 4 to 128 times; through the dose of 64 or 8 mug / mL, the curative effect of Xianfeng V on NDM-1 or CcrA producing medicine-resistance bacteria E.coli is improved by 32 times.

The invention discloses application of vanillic acid in inhibiting growth of multi-drug-resistance staphylococcus aureus. The inhibition effect of the vanillic acid on humanized multi-drug-resistancestaphylococcus aureus is put forward based on the fact that the vanillic acid has a good in-vitro killing effect on humanized multi-drug-resistance staphylococcus aureus which is resistant to linezolid, trimethoprim, gentamicin, ciprofloxacin, penicillin, cefazolin, clindamycin, vancomycin, oxacillin and piperacillin, and can inhibit the growth of multi-drug-resistance staphylococcus aureus, wherein the minimum bactericidal concentration is 2.4 mg / mL, and the minimum inhibitory concentration is 0.3 mg / mL. By means of the vanillic acid, drug-resistance infection of multi-drug-resistance staphylococcus aureus can be effectively relieved or solved, the mortality is reduced, a new idea is put forward for inhibition of humanized multi-drug-resistance staphylococcus aureus, and the vanillic acidhas important practical significance.

The invention discloses a Nocardia culture medium. The Nocardia culture medium is characterized in that the formulation for preparing 1000 ml of the culture medium contains 2-4 g of soluble starch, 10-20 g of bovine liver powder, 0.005-0.02 g of oxacillin, 3-5 million units of multisubtilin, 0.1-0.4 g of allithiamine, 0.01-0.2 g of inositol, 0.8-1.1 g of magnesium sulfate, 15-20 g of agar, and distilled water which is added to reach the total volume of 1000 ml. Compared with the prior art, the Nocardia culture medium has the characteristics of reliable detection and high separation rate.

The invention discloses a rhubarb acid ester derivative in the field of antibiotic compounds. The chemical structural formula of rhubarb acid ester is as shown in the formula (II), the formula (II) isshown in the description, wherein R is a chain substituent group of 1-5 carbon atoms or a naphthenic base or an aromatic hydrocarbon group of 3-6 carbon atoms. An antibiotic activity test proves thatthe rhubarb acid ester derivative with the novel structure has the antibiotic activity on methicillin-resistant staphylococcus aureus (MRSA). A plurality of targets have the outstanding antibiotic effect on methicillin-resistant staphylococcus aureus (MRSA), are superior to the reference drug oxacillin and is close to the reference drug vancomycin, and the rhubarb acid ester derivative can be served as a candidate compound to resist methicillin-resistant staphylococcus aureus (MRSA) and be researched.

The invention discloses a midget anti drug-tolerance staphylococcus aureus polypeptide comprised of passage structure domain to form ion channel colicine and staphylococcus aureu pheromone, as well as opposite coded nucleotide sequence and recombination plasmid contained said sequence. Wherein, the plupeptide can not induce bacteria to generate trsditional drug-tolerance by the mechnism that it forms directly ion channel on cell film of target cell to kill bacteria. This invention has more single antimicrobial spectrum without effect to Gram-negative bacteria of escherichia coli, shows at least 500 times effect to pheneazonecillin, and can be used as synergist to beta-lactam antibiotics.

Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria.

The invention discloses a macrolide compound and a synthesis method, a pharmaceutical composition and application of the compound. When the macrolide compound or the pharmaceutically acceptable salt thereof provided by the invention is used together with beta-lactam antibiotics, the effect of the beta-lactam antibiotics on inhibiting methicillin-resistant staphylococcus aureus can be obviously improved. A test result shows that the in-vitro synergistic effect is good, and the compound is a novel synergist, can relieve the drug resistance of methicillin-resistant staphylococcus aureus (MRSA) to oxacillin, and has a good market development prospect.

The invention relates to a composition of prodigiosins and oxacillin or derivatives of the oxacillin. The mass ratio of the prodigiosins to the oxacillin or the derivatives of the oxacillin is (1-2.55): 1. The invention further provides application of the composition in preparation of drugs for treating infectious diseases caused by methicillin-resistant staphylococcus aureus, and also provides amedicine for treating the infectious diseases caused by methicillin-resistant staphylococcus aureus. The antibacterial effect of the composition and the medicine containing the composition is obviously higher than that of two single components.

The invention discloses an application of 24-membered macrocyclic Schiff base in preparation of a drug for treating methicillin-resistant staphylococcus aureus infection. The 24-membered macrocyclic Schiff base is found to form a G-quadruplex structure with the core sequence of the MecA gene in the methicillin-resistant staphylococcus aureus through methods such as circular dichroism spectrum andWestern-Blot, so that the expression of the corresponding penicillin-binding protein PBP2a is inhibited. Pharmacological sensitivity experiments prove that the 24-membered macrocyclic Schiff base canreduce the minimum inhibitory concentration of methicillin-resistant staphylococcus aureus on oxacillin. When the use amount of the 24-membered macrocyclic Schiff base is 5 [mu] M, the minimum inhibitory concentration of methicillin-resistant staphylococcus aureus can be reduced to 0.5 [mu] g / mL to the minimum, and the effect of treating methicillin-resistant staphylococcus aureus infection by using beta-lactam drugs is achieved.